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BACKGROUND: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to
be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2
mutation carriers.
METHODS: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach.
RESULTS: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93–1.04, P¼0.5) or
BRCA2 (per-allele HR: 0.97, 95% CI: 0.89–1.06, P¼0.5) mutation carriers.
CONCLUSION: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
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Germ-line mutations in the BRCA1 and BRCA2 genes confer a high
lifetime risk of developing breast and other cancers. Estimates of
the cumulative risk of breast cancer to age 70 years vary from 40%
to 85% (Easton et al, 1995; Ford et al, 1998; Antoniou et al, 2003;
Chen et al, 2006; Milne et al, 2008). Other genetic and/or
environmental factors (modifiers) are likely to explain these
differences, at least in part. Because of the large sample size
required to identify such effects, few reliable associations have
been reported to date, all coming from the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA) initiative, which
was set up to provide large samples of BRCA1 and BRCA2
mutation carriers to reliably assess even modest associations with
single nucleotide polymorphisms (SNPs) (Chenevix-Trench et al,
2007). Recently, CIMBA assessed three SNPs in the FGFR2, TNRC9
and MAP3K1 genes that had been previously found by a genome-
wide association study to be associated with increased breast
cancer risk for women in the general population (Easton et al,
2007). Consistent associations were found for BRCA1 and/or
BRCA2 mutation carriers (Antoniou et al, 2008), indicating that
SNPs involved in the susceptibility to develop breast cancer in the
general population are good candidates to be tested as potential
modifiers in BRCA1 and BRCA2 mutation carriers.
The ERCC4 gene is involved in the nucleotide excision repair
(NER) pathway, which has led to the investigation of its role in the
susceptibility to develop different types of cancer including breast
cancer (Garcia-Closas et al, 2006; Mechanic et al, 2006; Moreno
et al, 2006; Kiyohara and Yoshimasu, 2007; Hooker et al, 2008;
Smith et al, 2008). We previously reported that the minor G allele
in a SNP on intron 1 of ERCC4 (rs744154) was associated with
protection from breast cancer in the general population (OR under
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of this finding, we aimed to assess ERCC4-rs744154 as a breast
cancer risk modifier in BRCA1 and BRCA2 mutation carriers. The
study was performed in two stages, the first comprising 837
mutation carriers from three CIMBA centres, and the second
comprising 15040 mutation carriers from all the CIMBA studies,
including those used in stage I.
MATERIALS AND METHODS
Subjects
Eligible subjects were female carriers of deleterious mutations in
BRCA1 and BRCA2 aged 18 years or older. Further details
regarding eligibility and the information collected from subjects
are described elsewhere (Antoniou et al, 2008). Subjects who
reported having ethnicity other than White European were
excluded. This gave a total of 15040 female mutation carriers
(9408 with mutations in BRCA1 and 5632 with mutations in
BRCA2), 8088 of whom had been diagnosed with breast cancer
(4956 and 3132 with mutations in BRCA1 and BRCA2, respec-
tively). All carriers participated in clinical or research studies at
the host institution under ethically approved protocols.
A total of 34 collaborating CIMBA studies, carried out in 18
countries, contributed genotype data for ERCC4-rs744154 to this
study. Details of each study along with the number of samples
included from each are provided in Table 1. Seven studies (CBCS,
GOG, ILUH, MSKCC, NNPIO, OSUCCG and IOVHBOCS) had not
participated in previous CIMBA collaborations (Antoniou et al,
2008). Subjects from the CNIO, HEBCS and MBCSG studies were
used in the first stage and comprised 837 mutation carriers (469 in
BRCA1 and 368 in BRCA2). All 9408 BRCA1 and 5632 BRCA2
mutation carriers CIMBA subjects were included in the second stage.
Genotyping
The genotyping platform used by each study is detailed in Table 1.
For 11 studies, matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF MS) was applied to
determine allele-specific primer extension products using Seque-
nom’s MassARRAY system and iPLEX technology (Sequenom, San
Diego, CA, USA). The design of oligonucleotides was carried out
according to the guidelines of Sequenom and performed using
MassARRAY Assay Design software (version 3.1). One study
determined genotypes by direct sequencing. Genotyping was
carried out for the remaining studies by nuclease assay (Taqman).
Taqman genotyping reagents were designed by Applied Biosystems
(Foster City, CA, USA) (http://www.appliedbiosystems.com/) as
Assays-by-Design. Genotyping was performed using the ABI
PRISM 7900HT, 7700 or 7500 Sequence Detection Systems
according to the manufacturer’s instructions. All studies complied
with CIMBA genotyping quality control (QC) standards (Antoniou
et al, 2008).
Table 1 Number of BRCA1 and BRCA2 mutation carriers by study
Study
Country of
residence BRCA1 BRCA2
Genotyping
platform
Breast Cancer Family Registry (BCFR) USA and Australia 492 356 Taqman
Copenhagen Breast Cancer Study (CBCS) Denmark 92 51 Taqman
CNIO Spain and Greece
a 149 198 Taqman
Deutsches Krebsforschungszentrum (DKFZ) Germany 68 27 Taqman
Hereditary Breast and Ovarian study Netherlands (DNA-HEBON) The Netherlands 768 293 iPlex
b
Epidemiological study of BRCA1 and BRCA2 mutation carriers (EMBRACE) UK and Eire 801 616 iPlex
b
Fox Chase Cancer Center (FCCC) USA 82 53 iPlex
b
German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) Germany 799 376 Taqman
Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) France 1123 565 Taqman
Gynecologic Oncology group (GOG) USA 391 275 Taqman
Georgetown (GTN) USA 29 17 iPlex
b
Hospital Clı ´nico San Carlos (HCSC) Spain 109 94 Taqman
Helsinki Breast Cancer Study (HEBCS) Finland 102 104 iPlex
b
Iceland Landspitali – University Hospital (ILUH) Iceland 86 Sequencing
Interdisciplinary Health Research International Team Breast Cancer Susceptibility
(INHERIT BRCAs)
Quebec-Canada 73 82 Taqman
Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab) Australia 488 388 iPlex
b
Mayo Clinic (MAYO) USA 214 118 iPlex
b
Milan Breast Cancer Study Group (MBCSG) Italy 344 218 Taqman
Modifier Study of Quantitative Effects on Disease (ModSQuaD) Czech Republic 271 128 Taqman
Memorial Sloan-Kettering Cancer Center (MSKCC) USA 255 157 Taqman
Medical University of Vienna (MUV) Austria 281 120 iPlex
b
National Cancer Institute (NCI) USA 156 73 Taqman
National Israeli Cancer Control Centre (NICCC) Israel 309 196 Taqman
N.N. Petrov Institute of Oncology (NNPIO) Russia 66 0 Taqman
Ontario Cancer Genetics Network (OCGN) Canada 219 170 Taqman
The Ohio State University Clinical Cancer Genetics Program (OSU CCG) USA 60 31 Taqman
Odense University Hospital (OUH) Denmark 217 131 Taqman
Istituto Oncologico Veneto (IOVHBOCS) Italy 93 88 Taqman
Pisa Breast Cancer Study (PBCS) Italy 72 40 iPlex
b
Sheba Medical Centre (SMC)-Tel Hashomer Israel 400 190 Taqman
Swedish Breast Cancer Study (SWE-BRCA) Sweden 411 120 iPlex
b
University of Turı ´n Breast Cancer Study (UTBCS) Italy 61 43 Taqman
University of California Irvine (UCI) USA 166 120 Taqman
University of Pennsylvania (UPENN) USA 247 108 iPlex
b
Total 9408 5632
aThe CNIO series consisted of mutation carriers from the Spanish Consortium for the Study of Genetic Modifiers of BRCA1 and BRCA2 and the NCSR Demokritos, Athens,
Greece.
bMutation carriers that failed genotyping are not included in the totals.
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To test for departure from Hardy–Weinberg equilibrium, a single
subject was randomly selected from each family and Pearson’s w
2
Test (1d.f.) was applied to genotypes from this sample set. The
association of ERCC4-rs744154 with breast cancer risk was
assessed by estimating hazard ratios (HR) and their corresponding
95% confidence intervals (CI) using weighted multivariable Cox
proportional hazards regression with robust estimates of variance
(Antoniou et al, 2005). For each mutation carrier, we modelled the
time to diagnosis of breast cancer from birth, censoring at the first
of the following events: bilateral prophylactic mastectomy, breast
cancer diagnosis, ovarian cancer diagnosis, death and last date
known to be alive. Subjects were considered affected if they were
censored at breast cancer diagnosis and unaffected otherwise. The
weighted cohort approach involves assigning weights separately to
affected and unaffected individuals such that the weighted
observed incidences in the sample agree with established estimates
for mutation carriers (Antoniou et al, 2003). This approach has
been shown to adjust for the bias in the HR estimates that is a
consequence of the ascertainment criteria used (Antoniou et al,
2005), which leads to an over-sampling of affected women.
Weights were assigned separately for carriers of mutations in
BRCA1 and BRCA2 and by age interval (o25, 25–29, 30–34, 35–
39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, X70).
We considered log-additive and codominant genetic models and
tested these by applying in the first case a Wald test based on the
log-HR estimate per allele and its standard error, and in the second
the w
2 equivalent of a Wald test (on 2 degrees of freedom [d.f.])
based on the log-HR estimates for heterozygotes (CG) and minor-
allele-homozygotes (GG) vs common homozygotes (CC) and the
corresponding variance–covariance matrix. Additional indepen-
dent variables included in all analyses were year of birth (o1930,
1930–1939, 1940–1949, 1950–1959, 1960–1969, X1970), study
centre and country. Heterogeneity in HRs by study centre was
assessed by the w
2 test described above, but applied to interaction
terms for the per-allele effect by centre (on 33d.f.). A number of
sensitivity analyses were applied, including censoring at bilateral
prophylactic oophorectomy (BPO), adjusting for BPO (as a time-
varying covariate), excluding data used in the initial analysis (from
CNIO, HEBCS and MBCSG) and excluding prevalent cases, defined
as those diagnosed 43 years before interview or DNA extraction.
In addition, an alternative analysis based on a previously described
retrospective likelihood approach (Chenevix-Trench et al, 2007)
was also applied using the pedigree analysis software MENDEL
(Lange et al, 1988).
All statistical analyses were carried out using Stata: Release 10
(StataCorp. 2007. Stata Statistical Software: Release 10.0. College
Station, TX: Stata Corporation LP) unless otherwise stated. Robust
estimates of variance were calculated using the cluster subcom-
mand, applied to an identifier variable unique to each family.
RESULTS AND DISCUSSION
It is thought that any SNP involved in the susceptibility to develop
breast cancer in the general population could also be a phenotypic
modifier in carriers of mutations in the high-risk susceptibility
genes BRCA1 and BRCA2. This has been confirmed in a recent
report from CIMBA in which minor alleles in three SNPs in the
FGFR2, TNRC9 and MAP3K1 genes, previously found to be
associated with increased breast cancer risk in the general
population (Easton et al, 2007), were found to increase breast
cancer risk in BRCA1 and/or BRCA2 mutation carriers as well
(Antoniou et al, 2008). We therefore aimed to investigate the role
of the rs744154 SNP in ERCC4 as a potential BRCA1/BRCA2 risk
modifier, based on our earlier finding that the minor G allele was
associated with breast cancer protection in the general population
(OR under a recessive model 0.61; P¼0.0002) (Milne et al, 2006).
This study was performed in two stages, the first analysing the
SNP in 837 carriers of mutations (469 in BRCA1 and 368 in
BRCA2) from three CIMBA studies (CNIO, HEBCS and MBCSG).
Results of the first stage are summarized in Table 2. We observed a
marginally significant association of the G allele in ERCC4-
rs744154 with breast cancer risk for both BRCA1 (HR: 0.78, 95%
CI: 0.60–1.00, P¼0.05) and BRCA2 (HR: 0.68, 95% CI: 0.45–1.02,
P¼0.06) mutation carriers. As this result was consistent with our
previously reported protective association in the general popula-
tion (Milne et al, 2006), we genotyped this SNP in subjects from
the remaining CIMBA studies and repeated the analysis in the
combined series of 9408 BRCA1 and 5632 BRCA2 mutation carriers
(see Table 2). However, when the whole CIMBA series was
analysed (stage II), there was no longer evidence of an association
with breast cancer risk for either BRCA1 (HR: 0.98, 95% CI: 0.93–
Table 2 Genotype frequencies of ERCC4-rs744154 by mutation and disease status and hazard ratio estimates from stages I and II
Genotype Unaffected (%) Affected (%) HR
a 95% CI P-value
Stage I
a
BRCA1 (n¼469) CC 104 (50) 148 (57) 1.00
CG 85 (41) 96 (37) 0.86 0.62–1.20
GG 19 (9) 17 (7) 0.49 0.24–1.01 0.1
b
Per allele 0.78 0.60–1.00 0.05
BRCA2 (n¼368) CC 73 (45) 109 (53) 1.00
CG 81 (49) 82 (40) 0.66 0.40–1.09
GG 10 (6) 13 (6) 0.50 0.17–1.47 0.2
b
Per allele 0.68 0.45–1.02 0.06
Stage II
BRCA1 (n¼9408) CC 2251 (51) 2603 (53) 1.00
CG 1836 (41) 1922 (39) 0.99 0.92–1.07
GG 365 (8) 431 (9) 0.96 0.83–1.10 0.8
b
Per allele 0.98 0.93–1.04 0.5
BRCA2 (n¼5632) CC 1288 (52) 1601 (51) 1.00
CG 1012 (40) 1300 (42) 1.05 0.93–1.18
GG 200 (8) 231 (7) 0.82 0.65–1.02 0.09
b
Per allele 0.97 0.89–1.06 0.5
a837 mutation carriers from CNIO, MBCSG and HBCS were included in stage I. Additional mutation carriers from these centres were later genotyped and included in stage II,
with carriers from other CIMBA centres. Total number of mutation carriers from these three centres included in the study is provided in Table 1.
b2-d.f. test.
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s1.04, P¼0.5) or BRCA2 (HR: 0.97, 95% CI: 0.89–1.06, P¼0.5)
mutation carriers. Several sensitivity analyses were performed (see
Materials and Methods) but results did not change substantially
and so those from the main analysis are presented in this report.
Subsequent to the initiation of this study, a study from the
Breast Cancer Association Consortium (BCAC), performed in
430000 breast cancer cases and 30000 controls has now found no
evidence for an association of rs744154 with breast cancer risk in
the general population (Gaudet et al, 2009). This is consistent with
the lack of association found for BRCA1 and BRCA2 mutation
carriers. These findings highlight the necessity of very large
collaborative efforts to obtain reliable conclusions in genetic
association studies. On the basis of the combined results obtained
from the BCAC analysis of sporadic breast cancer and the CIMBA
analysis of BRCA-related breast cancer – each the largest study of
its kind – there no longer seems to be convincing evidence that
ERCC4-rs744154 is associated with breast cancer risk.
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